Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
The 2018 Nobel Prize announcement recognized the discovery of the “entirely new principle for cancer therapy” of negative immune regulation. It also cited the pharmaceutical industry’s lack of interest. Ultimately, a small biotech company developed both the anti-CTLA-4 antibody Yervoy/ipilimumab, based on James Allison’s work, and the anti-PD-1 antibody Opdivo/nivolumab based on Tasuku Honjo’s work. This talk will discuss why pharmaceutical companies were not interested, why these products were developed by the biotech company Medarex, and how this example highlights the results of new research into the origins of the most innovative medicines of the past two decades.
